For Patients and Families

For Healthcare Professionals

Are you a healthcare professional?

Go back

09.05.2020

Resources from the KCNQ2 Cure Alliance

What is KCNQ2 Epilepsy? – KCNQ2 Cure Alliance

what does kcnq2 stand for

Keep reading

Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)

Discover this News

Biohaven Acquires Kv7 Ion Channel Platform For The Treatment Of Epilepsy And Other Neurologic Disorders From Channel Biosciences, A Subsidiary Of Knopp Biosciences

Discover this News

Knopp Biosciences NIH-funded Pain Program Advances to Third Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

Discover this News

Phase 2 Trial Evaluating the Effect of Dexpramipexole on Eosinophil Biomarkers and Lung Function in Asthma

Discover this News

Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function

Discover this News

Knopp Disclaimer

Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are undergoing clinical study to verify their safety and effectiveness.